Anthropic’s recent launch of a Bay Area wet lab for Claude models to run real-world biology experiments has become the central driver of trader sentiment on the lab-leak market. The company disclosed the facility in September 2026 amid broader AI efforts to accelerate biological research, prompting immediate market creation with implied probabilities remaining low at 3–10% through mid-2027. No confirmed pathogen escapes have occurred, and Anthropic’s public reports emphasize controlled evaluations rather than high-risk pathogen work. Key upcoming catalysts include further expansion of AI-assisted bio experiments, potential regulatory scrutiny from U.S. agencies on dual-use research, and any credible reporting on lab safety incidents. Traders view the low odds as reflecting both the early stage of operations and strict biosafety protocols typical in the sector.